Encorafenib Plus Binimetinib Improves Long-Term PFS, OS in BRAF V600-Mutant Melanoma - Cancer Therapy Advisor

An update from the COLUMBUS trial showed long-term benefits with encorafenib plus binimetinib, when compared with vemurafenib or encorafenib alone.

Encorafenib plus binimetinib can provide long-term benefits in patients with BRAF V600-mutant melanoma, according to research published in the Journal of Clinical Oncology. A 5-year update from the … [+3251 chars]

full article...